This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Introduction. Quetiapine: A 5-Year Update

Jeffrey A. Lieberman, MD, and Diana O. Perkins, MD, MPH

Published: December 31, 2002

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The treatment of schizophrenia changed in the 1950s with the discovery of conventional antipsychotics, such as chlorpromazine and haloperidol. In the ensuing decade, it became apparent that many patients would have an incomplete or partial response, with clinically significant positive symptoms remaining despite optimal dosing. It also became clear that typical antipsychotics were not effective against the most disabling aspects of schizophrenia, the negative symptoms and cognitive impairments.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 63

Quick Links: Neurologic and Neurocognitive , Neurology

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...